Consolidated Q2 FY27 revenue up 12.7%, PAT up 163% at Rs 395 lakh
MAKERSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.8 pts more than Nifty Microcap 250 and 8.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue from operations for Q2 FY27 ended 30 Sep 2026 rose 12.7% to Rs 4,821.01 lakh from Rs 4,277.16 lakh, while profit after tax attributable to owners jumped 162.5% to Rs 394.97 lakh from Rs 150.43 lakh. Consolidated half-year profit was Rs 545.40 lakh on revenue of Rs 9,098.17 lakh. Standalone Q2 was a loss of Rs 62.86 lakh versus Rs 107.50 lakh. Unaudited; auditor review unmodified.
Stronger consolidated profit and EPS of Rs 6.69 may support the stock, though standalone business remains loss-making.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.